{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:50:30Z","timestamp":1783979430236,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005907","name":"Institute for Humane Studies at George Mason University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005907","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005616","name":"Allergan Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005616","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019325","name":"The Grove Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson & Johnson Services Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["chestcc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST Critical Care"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.chstcc.2024.100117","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T19:42:56Z","timestamp":1733773376000},"page":"100117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anti-CD14 Treatment in Patients With Severe COVID-19 Clinical and Biological Effects in a Phase 2 Randomized Open-Label Adaptive Platform Clinical Trial"],"prefix":"10.1016","volume":"3","author":[{"given":"F. Linzee","family":"Mabrey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8193-909X","authenticated-orcid":false,"given":"Thomas R.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.","family":"Calfee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen D.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"LaCombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2076-5177","authenticated-orcid":false,"given":"Lamorna","family":"Brown-Swigart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Discacciati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5032-5266","authenticated-orcid":false,"given":"Martin","family":"Eklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7100-512X","authenticated-orcid":false,"given":"Susan R.","family":"Heckbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3039-8155","authenticated-orcid":false,"given":"Michael A.","family":"Matthay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Esserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Wurfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7-8","key":"10.1016\/j.chstcc.2024.100117_bib1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/17534259211051364","article-title":"TLRs in COVID-19: how they drive immunopathology and the rationale for modulation","volume":"27","author":"Mabrey","year":"2021","journal-title":"Innate Immun"},{"key":"10.1016\/j.chstcc.2024.100117_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cytogfr.2019.06.003","article-title":"CD14: biology and role in the pathogenesis of disease","volume":"48","author":"Wu","year":"2019","journal-title":"Cytokine Growth Factor Rev"},{"issue":"6","key":"10.1016\/j.chstcc.2024.100117_bib3","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.chom.2020.04.017","article-title":"Heightened innate immune responses in the respiratory tract of COVID-19 patients","volume":"27","author":"Zhou","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"6","key":"10.1016\/j.chstcc.2024.100117_bib4","first-page":"883","article-title":"Overly exuberant innate immune response to SARS-CoV-2 infection","volume":"27","author":"Zhou","year":"2020","journal-title":"SSRN Journal"},{"issue":"6","key":"10.1016\/j.chstcc.2024.100117_bib5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","article-title":"Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages","volume":"20","author":"Merad","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.chstcc.2024.100117_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-99705-y","article-title":"Dynamic alterations in monocyte numbers, subset frequencies and activation markers in acute and convalescent COVID-19 individuals","volume":"11","author":"Rajamanickam","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.chstcc.2024.100117_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.560381","article-title":"Increased serum levels of sCD14 and sCD163 indicate a preponderant role for monocytes in COVID-19 immunopathology","volume":"11","author":"G\u00f3mez-Rial","year":"2020","journal-title":"Front Immunol"},{"issue":"suppl 2","key":"10.1016\/j.chstcc.2024.100117_bib8","doi-asserted-by":"crossref","DOI":"10.1186\/cc9122","article-title":"The new sepsis marker, sCD14-ST, induction mechanism in the rabbit sepsis models","volume":"14","author":"Shirakawa","year":"2010","journal-title":"Crit Care"},{"issue":"suppl 1","key":"10.1016\/j.chstcc.2024.100117_bib9","first-page":"4811","article-title":"Stimulation of sCD14-ST (presepsin) secretion by peripheral blood mononuclear cells after Candida albicans lysate and lipopolysaccharide exposure","volume":"130","author":"Bazhenov","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.chstcc.2024.100117_bib10","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jiac.2015.04.011","article-title":"Phagocytosis by human monocytes is required for the secretion of presepsin","volume":"21","author":"Arai","year":"2015","journal-title":"J\u00a0Infect Chemother"},{"issue":"1","key":"10.1016\/j.chstcc.2024.100117_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12865-020-00362-z","article-title":"Can presepsin uniformly respond to various pathogens? An in\u00a0vitro assay of new sepsis marker","volume":"21","author":"Koizumi","year":"2020","journal-title":"BMC Immunol"},{"issue":"1","key":"10.1016\/j.chstcc.2024.100117_bib12","first-page":"93","article-title":"Presepsin (sCD14-ST) secretion and kinetics by peripheral blood mononuclear cells and monocytic THP-1 cell line","volume":"74","author":"Chenevier-Gobeaux","year":"2016","journal-title":"Ann Biol Clin (Paris)"},{"issue":"12","key":"10.1016\/j.chstcc.2024.100117_bib13","article-title":"Plasma soluble CD14 subtype levels are associated with clinical outcomes in critically ill subjects with coronavirus disease 2019","volume":"3","author":"Mabrey","year":"2021","journal-title":"Crit Care Explor"},{"issue":"2","key":"10.1016\/j.chstcc.2024.100117_bib14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.molimm.2014.05.008","article-title":"Toll-like receptor co-receptors as master regulators of the immune response","volume":"63","author":"Di Gioia","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.chstcc.2024.100117_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102836","article-title":"Targeting innate immunity by blocking CD14: novel approach to control inflammation and organ dysfunction in COVID-19 illness","volume":"57","author":"Martin","year":"2020","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.chstcc.2024.100117_bib16","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/09680519030090061301","article-title":"An overview of clinical studies in healthy subjects and patients with severe sepsis with IC14, a CD14-specific chimeric monoclonal antibody","volume":"9","author":"Axtelle","year":"2003","journal-title":"J\u00a0Endotoxin Res"},{"key":"10.1016\/j.chstcc.2024.100117_bib17","article-title":"Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial","volume":"58","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"5","key":"10.1016\/j.chstcc.2024.100117_bib18","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1097\/01.CCM.0000124870.42312.C4","article-title":"CD14 receptor occupancy in severe sepsis: results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14)","volume":"32","author":"Reinhart","year":"2004","journal-title":"Crit Care Med"},{"issue":"19","key":"10.1016\/j.chstcc.2024.100117_bib19","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19: final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.chstcc.2024.100117_bib20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chstcc.2024.100117_bib21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/bmjebm-2020-111536","article-title":"Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis","volume":"26","author":"Malik","year":"2021","journal-title":"BMJ Evidence-Based Medicine"},{"key":"10.1016\/j.chstcc.2024.100117_bib22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13054-021-03558-w","article-title":"Longitudinal assessment of IFN-I activity and immune profile in critically ill COVID-19 patients with acute respiratory distress syndrome","volume":"25","author":"Venet","year":"2021","journal-title":"Crit Care"},{"key":"10.1016\/j.chstcc.2024.100117_bib23","first-page":"A2626","volume":"203","author":"Kwon","year":"2021","journal-title":"Biomarkers of COVID-19, a longitudinal and retrospective assessment of a NYC 1st wave cohort"},{"issue":"12","key":"10.1016\/j.chstcc.2024.100117_bib24","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.148983","article-title":"Mesenchymal stromal cells reduce evidence of lung injury in patients with ARDS","volume":"6","author":"Wick","year":"2021","journal-title":"JCI Insight"},{"issue":"10","key":"10.1016\/j.chstcc.2024.100117_bib25","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S2213-2600(22)00215-6","article-title":"Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial","volume":"10","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.chstcc.2024.100117_bib26","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.4049\/jimmunol.166.5.3599","article-title":"IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans","volume":"166","author":"Verbon","year":"2001","journal-title":"J\u00a0Immunol"},{"issue":"7","key":"10.1016\/j.chstcc.2024.100117_bib27","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1073\/pnas.90.7.2744","article-title":"Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14","volume":"90","author":"Pugin","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.chstcc.2024.100117_bib28","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1084\/jem.20101111","article-title":"CD14 is a coreceptor of Toll-like receptors 7 and 9","volume":"207","author":"Baumann","year":"2010","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.chstcc.2024.100117_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104667","article-title":"Phase 2, randomized, double-blind, placebo-controlled multi-center trial of the clinical and biological effects of anti-CD14 treatment in hospitalized patients with COVID-19 pneumonia","volume":"93","author":"Mabrey","year":"2023","journal-title":"eBioMedicine"},{"key":"10.1016\/j.chstcc.2024.100117_bib30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.cca.2022.10.013","article-title":"Surfactant protein D (SP-D) as a biomarker of SARS-CoV-2 infection","volume":"537","author":"Salvioni","year":"2022","journal-title":"Clin Chim Acta"},{"issue":"9","key":"10.1016\/j.chstcc.2024.100117_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0272840","article-title":"Procalcitonin as a predictive marker in COVID-19: a systematic review and meta-analysis","volume":"17","author":"Kumar","year":"2022","journal-title":"PLoS One"}],"container-title":["CHEST Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949788424000716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949788424000716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T17:17:12Z","timestamp":1770311832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949788424000716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2949788424000716"],"URL":"https:\/\/doi.org\/10.1016\/j.chstcc.2024.100117","relation":{},"ISSN":["2949-7884"],"issn-type":[{"value":"2949-7884","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-CD14 Treatment in Patients With Severe COVID-19 Clinical and Biological Effects in a Phase 2 Randomized Open-Label Adaptive Platform Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"CHEST Critical Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chstcc.2024.100117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}],"article-number":"100117"}}